Navigation Links
Gardasil (Cervical Cancer) - Analysis and Forecasts to 2020
Date:10/18/2011

13

4.5.4 Public Health Advantage 13

4.5.5 Cost Effectiveness 13

4.5.6 Barriers to the Vaccination 13

4.6 Vaccine Evaluation 14

4.6.1 Efficacy 14

4.6.2 Safety 14

4.6.3 Dosing Convenience 15

4.6.4 Intensity of Competition 15

4.7 Sales forecast 16

4.7.1 Eligible population for Gardasil 16

4.7.2 Dosing 16

4.7.3 Market Penetration 16

4.7.4 Annual Cost of Therapy 17

4.7.5 Sales Projections of Gardasil 17

5 Cervical Cancer Vaccine Market: Appendix 24

5.1 Market Definitions 24

5.2 List of Abberiviations 24

5.3 Research Methodology 24

5.3.1 Coverage 25

5.3.2 Secondary Research 25

5.3.3 Forecasting 25

5.3.4 Population Approved to take Vaccine 26

5.3.5 Net Penetration of Vaccine 26

5.3.6 Net Annual Dosing 27

5.3.7 Annual Cost of Therapy 27

5.3.8 Primary Research 27

5.3.9 Expert Panels 27

5.4 Contact Us 27

5.5 Disclaimer 28

1.1 List of Tables

Table 1:Cervical Cancer, Estimated Incidences and Mortality, 2010-2020 5

Table 2: Estimated Prevalence of HPV in 9-26 years women 7

Table 3: Gardasil, Cervical Cancer Global, Sales Forecast ($m), 2006–2020 17

Table 4: Gardasil, Cervical Cancer, the US, Sales Forecast ($m), 2006–2020 18

Table 5: Gardasil, Cervical Cancer, UK, Sales Forecast ($m), 2006–2020 19

Table 6: Gardasil, Cervical Cancer, France, Sales Forecast ($m), 2006–2020 20

Table 7: Gardasil, Cervical Cancer, Germany, Sales Forecast ($m), 2006–2020 21

Table 8: Gardasil, Cervical Cancer, Italy, Sales Forecast ($m), 2006–2020 22

Table 9: Gardasil, Cervical Cancer, Spain, Sales Forecast ($m), 2006–2020 23

1.2 List of Figures

Figure 1: Estimated Prevalence of HPV in Women Aged between 9-26 Years in the US,EU-5 and Japan, 2010-2020 1

Figur
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA: Gardasil Approved to Prevent Anal Cancer
2. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
3. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
4. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
5. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
6. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
7. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
8. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
11. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Covance Inc. (NYSE: CVD ) today reported ... Net revenue was $639 million, representing 8.0% growth from ... the company reported earnings of $0.29 per diluted share ... earnings per diluted share of $0.95, up 21.5% over ... asset impairment charges totaling $52.6 million, or $0.61 per ...
(Date:7/29/2014)... , July 29, 2014 New high priced ... Part D by a projected $2.9 to $5.8 billion ... actuarial firm Milliman released today by the Pharmaceutical Care ... premiums could increase by as much as 8.6 percent ... drugs, including Sovaldi and Olysio. The study ...
(Date:7/29/2014)... SPRINGS, Colo. , July 29, 2014 ... catheter (MARC) which could allow physicians to see and ... may hold promise, according to study authors who released ... (SNIS) 11 th Annual Meeting in ... stand to advance the field of neurointervention, a specialty ...
Breaking Medicine Technology:Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3
(Date:7/30/2014)... TX (PRWEB) July 30, 2014 ... the increase of personal health expenditure as well ... health care system, China diagnostic reagent industry has ... occupy over 90%. In 2013, Chinese in vitro ... RMB16.61 billion came from in vitro diagnostic reagents. ...
(Date:7/30/2014)... According to the Nasal Polyps Treatment Miracle ... guide that teaches people how to cure their nasal ... to readers the horrible truth about conventional treatments for nasal ... this book, people will learn how to prevent symptoms ... nasal infections. , Nasal Polyps Treatment Miracle, as it is ...
(Date:7/30/2014)... Francisco, CA (PRWEB) July 30, 2014 ... capture and physician communication, launched an Observation Result ... in the hospital. pMD’s cardiology customers are using ... optimize revenue for their test interpretations for electrocardiograms, ... interprets tests in the hospital, the cardiology system ...
(Date:7/29/2014)... Rancho Cucamonga, CA (PRWEB) July 29, 2014 ... “Realistic Ways to Make More Money in 30 Days” E-book. ... that anyone can use to make extra cash. Examples include ... and utilizing unique free websites that help people monetize the ... bedroom, and even unused items they can find in their ...
(Date:7/29/2014)... Dignity Sciences Limited, a privately held biopharmaceutical company, ... trial with DS107G, an oral formulation of Dihomo Gamma ... placebo-controlled, double-blind, single-ascending and multiple dose Phase I clinical ... food on DS107G in healthy subjects. , The ... both single and multiple oral doses over 28 days, ...
Breaking Medicine News(10 mins):Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 2Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 3Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 4Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 3Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Create Indestructible Wealth Launches Innovative E-Book: “Realistic Ways to Make More Money in 30 Days” 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2
... Interleukin Genetics, Inc. (NYSE Alternext US: ILI) announced ... on Monday, March 9, 2009, at 4:30 p.m. EDT to ... results, and provide an update on recent corporate developments. To ... The live Webcast and replay access of the teleconference will ...
... Inc. (NYSE: CRE ), today announced that it will release ... market opens on Monday, March 16, 2009.The Company will host ... a.m. Eastern Time to discuss fourth quarter and year end ... dialing 800-240-2430 or by visiting the Company,s website at ...
... ... physicians and specialists , Kuala ... Asia the release of Centricity PACS Web Diagnostic (WebDX),a new Web-based ... RIS/ PACS, which bring comprehensive detailed patient,history to a single patient ...
... OF PRUSSIA, Pa., Feb. 27 Fourth quarter of ... Realty Income Trust (NYSE: UHT ) announced today ... net loss was $870,000, or $.07 per diluted share, as ... per diluted share, during the comparable quarter in the prior ...
... University of Pittsburgh Medical Center (UPMC) and Paphos Plantations Ltd. (PPL) - ... collaborating to develop a world-class health care center in Paphos, Cyprus, designed ... and foreign visitors to this Mediterranean island. , ... Pittsburgh, PA and ...
... to the media regarding the PLoS Medicine article published online ... patient who developed "brain tumors" (glioneuronal neoplasms) after undergoing repeated ... 2001. , ... San Diego, California ...
Cached Medicine News:Health News:GE Healthcare Introduces New Web-Based Diagnostic Viewer with Workflow Integration and Streaming Technology for Hospitals in Asia 2Health News:GE Healthcare Introduces New Web-Based Diagnostic Viewer with Workflow Integration and Streaming Technology for Hospitals in Asia 3Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 2Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 3Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 4Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 5Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 6Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 7Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 8Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 9Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 10Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 11Health News:Universal Health Realty Income Trust Reports 2008 Fourth Quarter and Full Year Financial Results 12Health News:University of Pittsburgh Medical Center to Manage New Health Center in Cyprus 2Health News:University of Pittsburgh Medical Center to Manage New Health Center in Cyprus 3Health News:University of Pittsburgh Medical Center to Manage New Health Center in Cyprus 4Health News:Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article 2Health News:Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article 3Health News:Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article 4Health News:Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article 5
Includes conservation device, standard cannula, batteries and instruction booklet....
Oxygen Conservation Device. Bypass 6203: Turn knob....
... designed to grasp suture, and also ... useful for adjusting suture tension for ... closed, the tips act as a ... designed to fine tune the suture ...
... new CVD Diamond Knives. New advancements in ... diamonds to be used at a more ... stromal reapproximation, enhances healing, and insures a ... uses, and are available in a variety ...
Medicine Products: